A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2004
11/17/2004	EP1476018A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
11/17/2004	EP1401442B1 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
11/17/2004	EP1390063B1 Pharmaceutical dosage form of amorphous nelfinavir mesylate
11/17/2004	EP1303297B1 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency
11/17/2004	EP1303283B1 Use of noble metals for the manufacture of a medicament to treat hyperproliferative skin disorders and diseases
11/17/2004	EP1283854B1 Solutizing agents
11/17/2004	EP1254229B1 Vector constructs for gene-therapy mediated radionuclide therapy of undifferentiated and medullary thyroid carcinomas and non-thyroidal tumours and the metastases thereof
11/17/2004	EP1148895B1 Thermo-reversible polymer for intralumenal implant
11/17/2004	EP1102793B1 A process for the preparation of aqueous dispersions of latex particles having a heterogeneous morphology, the latex particles obtainable with the process, the dispersions and redispersible powders, as well as the use thereof
11/17/2004	EP1090037B1 Divalent antibody fragments conjugated to PEG
11/17/2004	EP1073469B1 Stable mitoxantron solutions
11/17/2004	EP1037649A4 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
11/17/2004	EP0928190B1 Nucleic acid particle delivery
11/17/2004	EP0897392B1 Peptides binding sh3 domain of cortactin and their use
11/17/2004	CN1547617A Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
11/17/2004	CN1547542A Stackable low depth tray
11/17/2004	CN1547487A Aqueous air foam
11/17/2004	CN1547484A Pharmaceutical dosage form of amorphous nelfinavir mesylate
11/17/2004	CN1547479A Pharmaceutical combination prepared by cannabis extract
11/17/2004	CN1547477A Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
11/17/2004	CN1547475A Dermal therapy using phosphate derivatives of electron transfer agents
11/17/2004	CN1547474A Skin-permeable selective cyclooxygenase-2 inhibitor composition
11/17/2004	CN1547469A Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof
11/17/2004	CN1547467A Compositions containing itraconazole and their preparation methods
11/17/2004	CN1547466A Extended release oral dosage form
11/17/2004	CN1547464A Prolonged release bioadhesive therapeutic systems
11/17/2004	CN1546678A Digestion tolerant starch and its preparation method and uses
11/17/2004	CN1546549A Bio-degradability polyester block macromolecule copolymer, preparation method and uses
11/17/2004	CN1546173A Anticancer nanometer targeted administered prescription
11/17/2004	CN1546168A Preparing method of liposome endothelial chalone
11/17/2004	CN1546068A Modified technique for making zedoary turmeric oil and glucose injection
11/17/2004	CN1546040A Compisition as substitution of phthalocyanine cooperator and low density lipoprotein and its preparation process
11/17/2004	CN1546006A Preparation method of biodegradable polymer pharmaceutical microsphere
11/17/2004	CN1176137C Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine
11/17/2004	CN1176010C Modified nano silicon particles
11/17/2004	CN1175905C Polycaprolactone-brufen composition and its preparation method and use
11/17/2004	CN1175901C Stable water solution of interferon
11/17/2004	CN1175820C Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders
11/17/2004	CA2470177A1 System and method for controlling user interface properties with data
11/16/2004	US6818672 Treating endometriosis or infertility, or improving fertility
11/16/2004	US6818671 Nimesulide containing topical pharmaceutical compositions
11/16/2004	US6818662 N-(3-chloro-4-morpholin-4-yl)phenyl-n'-hydroxyimidoformamidine containing sulfobutyl ether beta-cyclodextrin to increase the solubility; especially a freeze-dried injectable preparation.
11/16/2004	US6818630 Biologically active materials
11/16/2004	US6818627 Nuclear localization sequence fragment of hiv-1 vpr protein conjugated to nucleotide; drug delivery, antiproliferative agents
11/16/2004	US6818615 Antitumor, anticancer agents; synergistic mixture
11/16/2004	US6818613 A parenteral sustained-release formulation of e.g., erythropoietin, that is easily manufactured, safe, stable and efficient comprising the protein, a buffer, tonicity agent and sodium carboxymethylcellulose
11/16/2004	US6818611 Stabilized bioactive peptides and methods of identification, synthesis and use
11/16/2004	US6818230 Antiproliferative effect can be achieved by subjecting conditioned medium obtained by culturing the structures of the invention in culture medium to filtration; anticancer agents
11/16/2004	US6818226 Dermal penetration enhancers and drug delivery systems involving same
11/16/2004	US6818224 Using fluid pharmaceutical which allows the controlled release of at least one active substance and which comprises active substance, phospholipid, solvent, fatty acid and can form gel instantaneously for therapy of periodontitis
11/16/2004	US6818213 Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
11/16/2004	US6818207 Artificial nail compositions and related method
11/16/2004	US6818205 Use of fluorescent whitening agents
11/16/2004	US6818199 Intravenous delivery of radiographic nanoparticulate contrast agent
11/16/2004	CA2059692C Pneumoccoccal polysaccharide conjugate vaccine
11/16/2004	CA2030988C Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides
11/11/2004	WO2004097423A1 Secreted polypeptide species reduced cardiovascular disorders
11/11/2004	WO2004097017A2 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
11/11/2004	WO2004096998A2 Nanoparticular tumor targeting and therapy
11/11/2004	WO2004096989A2 Single chain antigen-binding polypeptides for polymer conjugation
11/11/2004	WO2004096826A2 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
11/11/2004	WO2004096285A2 Anti-infective phosphonate conjugates
11/11/2004	WO2004096284A1 Method for the preparation of molecular complexes
11/11/2004	WO2004096282A1 Hydrophilic blend gel
11/11/2004	WO2004096281A1 Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof
11/11/2004	WO2004096280A1 Composition containing medicine extremely slightly soluble in water and method for preparation thereof
11/11/2004	WO2004096279A1 Composition for injection
11/11/2004	WO2004096275A1 Instrument for inducing cytokine and method of inducing cytokine
11/11/2004	WO2004096271A1 Methods for treating cancer using an immunotoxin
11/11/2004	WO2004096266A1 Improved physical stability of insulin formulations
11/11/2004	WO2004096263A2 Human serum albumin-free stabilized interferon liquid formulations
11/11/2004	WO2004096258A1 Compositions and methods for treatment of psoriasis
11/11/2004	WO2004096254A2 Transferrin conjugates for tumor treatment
11/11/2004	WO2004096247A1 Instrument for inducing cytokine and method of inducing cytokine
11/11/2004	WO2004096234A2 Kinase inhibitor phosphonate conjugates
11/11/2004	WO2004096233A2 Nucleoside phosphonate conjugates
11/11/2004	WO2004096207A1 Body-temperature lowering depressant
11/11/2004	WO2004096192A1 Fast dissolving orally consumable films containing a sucralose as a sweetener
11/11/2004	WO2004096191A1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
11/11/2004	WO2004096188A1 Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof
11/11/2004	WO2004096179A1 Zinc-containing sustained-release composition, its preparation, and method for producing the same
11/11/2004	WO2004096174A1 Fast dissolving orally consumable films containing pharmaceutically active agents
11/11/2004	WO2004096136A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
11/11/2004	WO2004096117A2 Drug delivery systems comprising transferrin-nucleic acid conjugates
11/11/2004	WO2004073743A3 Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions
11/11/2004	WO2004073597A3 Bioadhesive liquid composition which is substancially free of water
11/11/2004	WO2004071452A3 Random and non-random alkylene oxide polymer alloy compositions
11/11/2004	WO2004058842A9 Method for the production of an active molecule vector used to diffuse active substances and vector thus obtained
11/11/2004	WO2004020404A3 Modified transferin-antibody fusion proteins
11/11/2004	WO2004014849A3 Isosorbide mononitrate compositions and methods of their use
11/11/2004	WO2003097356A9 Camptothecin derivatives and polymeric conjugates thereof
11/11/2004	WO2003087411A8 Method to inhibit cell growth using oligonucleotides
11/11/2004	WO2003070912A3 RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/11/2004	WO2003070885A3 SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE
11/11/2004	US20040225140 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
11/11/2004	US20040225077 tissue adhesion; hemostatic agents; biocompatibility gel ; in vivo administering of a drug
11/11/2004	US20040225022 Propofol formulation containing reduced oil and surfactants
11/11/2004	US20040224932 crystal structure; antiinflammatory agents; antiallergens
11/11/2004	US20040224925 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
11/11/2004	US20040224924 Programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or weakly active and non-toxic metabolite when the parent drug compound is administered, comprising modifying the parent drug compound by forming one or more of a predetermined chemical arrangement

1 ... 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 ... 1712